Companies Innoviva, Inc.
Innoviva (INVA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Innoviva, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers44th pct.Of 16 peer CEOs
CEO pay, last three years
- $868,648FY2023
- $2,716,420FY2024
- $5,400,197FY2025
CEO total pay was $5,400,197 in fiscal 2025, up from $2,716,420 in fiscal 2024.
FY2025: salary $600,000 · bonus $378,000 · stock awards $2,649,982 · option awards $1,748,882
Executives and directors
Pavel Raifeld · CEOMarianne Zhen · Chief Accounting OfficerStephen Basso · PresidentDerek A. Small · Independent DirectorJules Haimovitz · Independent DirectorMark A. DiPaolo · Independent DirectorOdysseas D. Kostas · Independent DirectorSapna Srivastava · Independent DirectorSarah J. Schlesinger · Independent Director
Frequently asked questions
Who was the highest-paid executive at Innoviva, Inc. in fiscal 2025?
As disclosed, Pavel Raifeld (Chief Executive Officer) was the highest-paid executive at Innoviva, Inc. in fiscal 2025, with total compensation of $5,400,197.
How does Innoviva, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Pavel Raifeld's total compensation ranked at the 44th percentile of Innoviva, Inc.'s disclosed peer group.
What is Innoviva, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Innoviva, Inc.'s CEO-to-median employee pay ratio was 12.3:1.
How did shareholders vote on Innoviva, Inc.'s executive compensation?
As disclosed, 94.95% of shareholders supported Innoviva, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Innoviva, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Innoviva, Inc. reported total board compensation of $1,393,990 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Pavel Raifeld | $600,000 | $378,000 | $2,649,982 | $1,748,882 | $0 | $0 | $23,333 | $5,400,197 |
| Chief Executive Officer | ||||||||
| Stephen Basso | 475,000 | 223,493 | 691,087 | 765,348 | 0 | 0 | 18,348 | 2,171,276 |
| Chief Financial Officer and President of IST | ||||||||
| Marianne Zhen | 420,000 | 245,438 | 161,599 | 229,989 | 0 | 0 | 25,833 | 1,082,859 |
| Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Pavel Raifeld | $5,400,197 | $2,716,420 | $868,648 | ↑ +2,683,777 |
| Stephen Basso | 2,171,276 | 1,009,797 | 1,182,051 | ↑ +1,161,479 |
| Marianne Zhen | 1,082,859 | 967,319 | 924,209 | ↑ +115,540 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The primary goals of our executive compensation programs are to (i) fairly compensate and reward executives for performance, (ii) attract and retain highly qualified executives, and (iii) align executives long-term interests with those of our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Meridian |
| Clawback policy | True |
| Anti-hedging | — |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Pavel Raifeld | OPTION | 2025-03-14 | — | — | 243,750 | — | $1,748,882 |
| Marianne Zhen | OPTION | 2025-02-24 | — | — | 30,300 | — | 229,989 |
| Pavel Raifeld | RSU | 2025-03-14 | — | — | 37,377 | — | 649,986 |
| Marianne Zhen | RSU | 2025-02-24 | — | — | 8,938 | — | 161,599 |
| Stephen Basso | RSU | 2025-11-03 | — | — | 27,609 | — | 499,999 |
| Stephen Basso | RSU | 2025-02-24 | — | — | 10,569 | — | 191,088 |
| Stephen Basso | OPTION | 2025-02-24 | — | — | 100,831 | — | 765,348 |
| Pavel Raifeld | RSU | 2025-11-03 | — | — | 110,436 | — | 1,999,996 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Pavel Raifeld | $2,649,982 | $0 | $1,748,882 | 0.0% |
| Marianne Zhen | 161,599 | 0 | 229,989 | 0.0% |
| Stephen Basso | 691,087 | 0 | 765,348 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Marianne Zhen | RSU | 418 | — | $8,356 |
| Marianne Zhen | Option | 937 | 18.68 | — |
| Marianne Zhen | RSU | 4,482 | — | 89,595 |
| Marianne Zhen | RSU | 6,048 | — | 120,900 |
| Marianne Zhen | Option | 6,250 | 12.2 | — |
| Stephen Basso | RSU | 6,804 | — | 136,012 |
| Marianne Zhen | RSU | 8,938 | — | 178,671 |
| Stephen Basso | RSU | 10,569 | — | 211,274 |
| Marianne Zhen | Option | 12,949 | 14.88 | — |
| Stephen Basso | Option | 14,568 | 14.88 | — |
| Pavel Raifeld | Option | 18,750 | 16.31 | — |
| Stephen Basso | RSU | 27,609 | — | 551,904 |
| Marianne Zhen | Option | 30,300 | 18.08 | — |
| Pavel Raifeld | RSU | 37,377 | — | 747,166 |
| Pavel Raifeld | Option | 42,187 | 14.88 | — |
| Pavel Raifeld | Option | 56,250 | 18 | — |
| Stephen Basso | Option | 75,000 | 12.75 | — |
| Pavel Raifeld | Option | 84,375 | 20 | — |
| Stephen Basso | Option | 100,831 | 18.08 | — |
| Pavel Raifeld | RSU | 110,436 | — | 2,207,415 |
| Pavel Raifeld | Option | 243,750 | 17.39 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jules HaimovitzIndependent | $150,000 | $224,995 | $72,241 | — | — | $447,236 |
| Mark A. DiPaoloIndependent | 105,838 | 224,995 | 72,241 | — | — | 403,074 |
| Sarah J. SchlesingerIndependent | 99,615 | 224,995 | 72,241 | — | — | 396,851 |
| Derek A. SmallIndependent | 86,634 | 224,995 | 72,241 | — | — | 383,870 |
| Sapna SrivastavaIndependent | 32,692 | — | — | — | — | 32,692 |
| Odysseas D. KostasIndependent | 19,231 | — | — | — | — | 19,231 |
Board fee structure and ownership guideline
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | beginning after five years of service, non-employee directors are expected to hold shares...with a value equal to at least ten times their annual base cash retainer. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $494,010 |
| Equity awards (grant-date value) | $899,980 |
| All other compensation | $0 |
| Total cost of the board | $1,393,990 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Innoviva as a peer
Companies that benchmark against INVA
7 companies name INVA as a compensation peer
- AMARIN CORP PLC\UKAMRNFY2025
- ARDELYX, INC.ARDXFY2025
- Aurinia Pharmaceuticals Inc.AUPHFY2025
- CERUS CORPCERSFY2025
- HERON THERAPEUTICS, INC. /DE/HRTXFY2025
- LIGAND PHARMACEUTICALS INCLGNDFY2025
- SIGA TECHNOLOGIES INCSIGAFY2025
Each company listed discloses INVA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INVA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
MGNX MacroGenics, Inc.TVTX Travere Therapeutics, Inc.AGIO Agios Pharmaceuticals, Inc.CHRS Coherus BioSciences, Inc.AMRN Amarin Corporation plcSVRA Savara Inc.ARVN Arvinas, Inc.LGND Ligand Pharmaceuticals Inc.XNCR Xencor, Inc.TBPH Theravance Biopharma, Inc.XERS Xeris Biopharma Holdings, Inc.COGT Cogent Biosciences, Inc.CPRX Catalyst Pharmaceuticals, Inc.MORF Morphic Holding, Inc.SWTX SpringWorks Therapeutics, Inc.VRNA Verona Pharma plc
Peer reciprocity
The companies Innoviva, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences, Inc. | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Verona Pharma plc | 2024 | David Zaccardelli | 873,015 | 18,089,500 | 0 | 480,158 | 19,456,473 |
| 3 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 4 | Ligand Pharmaceuticals Inc. | 2025 | Todd Davis | 724,500 | 5,520,493 | 4,441,120 | 764,400 | 11,472,095 |
| 5 | Morphic Holding, Inc. | 2023 | Praveen Tipirneni | 613,502 | 3,742,960 | 4,121,756 | 412,966 | 8,907,684 |
| 6 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 7 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 8 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 9 | Xencor, Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 10 | Innoviva, Inc. | 2025 | Pavel Raifeld | 600,000 | 2,649,982 | 1,748,882 | 0 | 5,400,197 |
| 11 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 12 | Xeris Biopharma Holdings, Inc. | 2025 | John Shannon | 742,334 | 2,848,000 | 838,615 | 607,971 | 5,042,584 |
| 13 | Savara Inc. | 2025 | Matthew Pauls | 660,000 | 3,870,000 | 0 | 297,000 | 4,845,000 |
| 14 | Amarin Corporation plc | 2025 | Aaron Berg | 725,667 | 1,391,250 | 493,975 | 588,300 | 3,540,366 |
| 15 | Coherus BioSciences, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 16 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 17 | Theravance Biopharma, Inc. | 2025 | Rick Winningham | 1,047,431 | 0 | 0 | 419,182 | 1,472,019 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Innoviva, Inc. | 105% | not disclosed | not disclosed | Meridian |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Amarin Corporation plc | 107.75% | Options 75 · RSU 25 | not disclosed | Pearl Meyer |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Catalyst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Cogent Biosciences, Inc. | 135% | not disclosed | No | Compensia |
| Coherus BioSciences, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Ligand Pharmaceuticals Inc. | 150% | not disclosed | No | Aon |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Morphic Holding, Inc. | 120% | Stock Options 50 · RSU 50 | not disclosed | Aon |
| Savara Inc. | 90% | RSU 100 | not disclosed | Aon |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Theravance Biopharma, Inc. | not disclosed | RSU 100 | not disclosed | Frederic W. Cook & Co. (FW Cook) |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Verona Pharma plc | not disclosed | PRSU 75 · RSU 25 | not disclosed | Aon |
| Xencor, Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Xeris Biopharma Holdings, Inc. | 125% | not disclosed | not disclosed | Aon Consulting, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-04 | 56,243,880 | 2,836,001 | 158,046 | 94.95% | Passed |
| 2025 | 2025-05-19 | 45,767,649 | 2,070,275 | 187,652 | 95.3% | Passed |
| 2024 | 2024-06-17 | 52,833,150 | 1,146,788 | 19,575 | 97.84% | Passed |
| 2023 | 2023-05-22 | 51,955,275 | 2,512,795 | 31,010 | 95.39% | Passed |
| 2022 | 2022-04-25 | 51,473,540 | 1,726,447 | 104,542 | 96.57% | Passed |
| 2021 | 2021-05-14 | 48,107,045 | 35,542,106 | 134,970 | 57.42% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-04 | 94.95%a |
| 2025 | 2025-05-19 | 95.3%b |
| 2024 | 2024-06-17 | 97.84%c |
a. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 12.3 : 1 |
|---|---|
| CEO total compensation | $5,400,197 |
| Median employee compensation | $437,552 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jules Haimovitz | Director | 2026-05-04 | A | 10,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Basso | Chief Financial Officer | 2026-05-04 | A | 37,994 | 0 | 0 | Common | Form 4 ↗ |
| Derek A. Small | Director | 2026-05-04 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marianne Zhen | Chief Accounting Officer | 2026-05-04 | A | 31,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah J. Schlesinger | Director | 2026-05-04 | A | 9,786 | 0 | 0 | Common | Form 4 ↗ |
| Jules Haimovitz | Director | 2026-05-04 | A | 9,786 | 0 | 0 | Common | Form 4 ↗ |
| Sarah J. Schlesinger | Director | 2026-05-04 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pavel Raifeld | Director | 2026-05-04 | A | 312,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek A. Small | Director | 2026-05-04 | A | 9,786 | 0 | 0 | Common | Form 4 ↗ |
| Marianne Zhen | Chief Accounting Officer | 2026-05-04 | A | 12,766 | 0 | 0 | Common | Form 4 ↗ |
| Pavel Raifeld | Director | 2026-05-04 | A | 126,646 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Basso | Chief Financial Officer | 2026-05-04 | A | 93,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark A. DiPaolo | Director | 2026-05-04 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark A. DiPaolo | Director | 2026-05-04 | A | 9,786 | 0 | 0 | Common | Form 4 ↗ |
| Pavel Raifeld | Director | 2026-05-15 | A | 1,123 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Basso | Chief Financial Officer | 2026-05-15 | A | 1,123 | 0 | 0 | Common | Form 4 ↗ |
| Josephine Linden | Director | 2026-05-18 | A | 9,461 | 0 | 0 | Common | Form 4 ↗ |
| Josephine Linden | Director | 2026-05-18 | A | 5,733 | 0 | 0 | Common | Form 4 ↗ |
| Josephine Linden | Director | 2026-05-18 | A | 9,166 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marianne Zhen | Chief Accounting Officer | 2026-05-20 | D | 1,127 | 22 | 25,064 | Common | Form 4 ↗ |
| Pavel Raifeld | Director | 2026-05-20 | D | 1,130 | 22 | 25,131 | Common | Form 4 ↗ |
| Stephen Basso | Chief Financial Officer | 2026-05-20 | D | 559 | 22 | 12,432 | Common | Form 4 ↗ |
| Pavel Raifeld | Director | 2026-08-20 | D | 1,130 | 21 | 23,730 | Common | Form 4 ↗ |
| Marianne Zhen | Chief Accounting Officer | 2026-08-20 | D | 1,127 | 21 | 23,667 | Common | Form 4 ↗ |
| Stephen Basso | Chief Financial Officer | 2026-08-20 | D | 558 | 21 | 11,718 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (68 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Pavel Raifeld. DEF 14A, filed 2026-03-24. Section “Summary Compensation Table”. As printed: 5,400,197. View filing ↗
- Section 01, Stephen Basso. DEF 14A, filed 2026-03-24. Section “Summary Compensation Table”. As printed: 2,171,276. View filing ↗
- Section 01, Marianne Zhen. DEF 14A, filed 2026-03-24. Section “Summary Compensation Table”. As printed: 1,082,859. View filing ↗
- Section 03, Pavel Raifeld OPTION. DEF 14A, filed 2026-03-24. Section “THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDSVOTE &” · grants of plan-based awards table. View filing ↗
- Section 03, Marianne Zhen OPTION. DEF 14A, filed 2026-03-24. Section “THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDSVOTE &” · grants of plan-based awards table. View filing ↗
- Section 03, Pavel Raifeld RSU. DEF 14A, filed 2026-03-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Marianne Zhen RSU. DEF 14A, filed 2026-03-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Stephen Basso RSU. DEF 14A, filed 2026-03-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Stephen Basso RSU. DEF 14A, filed 2026-03-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Stephen Basso OPTION. DEF 14A, filed 2026-03-24. Section “THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDSVOTE &” · grants of plan-based awards table. View filing ↗
- Section 03, Pavel Raifeld RSU. DEF 14A, filed 2026-03-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-24. Section “CEO Pay Ratio”. As printed: 12.3 : 1. View filing ↗
- Section 08, Jules Haimovitz. DEF 14A, filed 2026-03-24. Section “Director Compensation”. As printed: 447,236. View filing ↗
- Section 08, Mark A. DiPaolo. DEF 14A, filed 2026-03-24. Section “Director Compensation”. As printed: 403,074. View filing ↗
- Section 08, Sarah J. Schlesinger. DEF 14A, filed 2026-03-24. Section “Director Compensation”. As printed: 396,851. View filing ↗
- Section 08, Derek A. Small. DEF 14A, filed 2026-03-24. Section “Director Compensation”. As printed: 383,870. View filing ↗
- Section 08, Sapna Srivastava. DEF 14A, filed 2026-03-24. Section “Director Compensation”. As printed: 32,692. View filing ↗
- Section 08, Odysseas D. Kostas. DEF 14A, filed 2026-03-24. Section “Director Compensation”. As printed: 19,231. View filing ↗
- Section 02, Jules Haimovitz 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Basso 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek A. Small 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marianne Zhen 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah J. Schlesinger 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jules Haimovitz 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah J. Schlesinger 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pavel Raifeld 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derek A. Small 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marianne Zhen 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pavel Raifeld 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Basso 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark A. DiPaolo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark A. DiPaolo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pavel Raifeld 2026-05-15. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Basso 2026-05-15. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Josephine Linden 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Josephine Linden 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Josephine Linden 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marianne Zhen 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pavel Raifeld 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Basso 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pavel Raifeld 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marianne Zhen 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Basso 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-04. Item 5.07 · say-on-pay result. As reported: 94.95% (votes for as printed: 56,243,880). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-21. Item 5.07 · say-on-pay result. As reported: 95.3% (votes for as printed: 45,767,649). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-20. Item 5.07 · say-on-pay result. As reported: 97.84% (votes for as printed: 52,833,150). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 494,010 + equity 899,980 + all other 0 = 1,393,990, summed across the director compensation table rows.
- Cogent Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. View filing ↗
- Verona Pharma plc, Section 10b CEO total. DEF 14A, filed 2025-03-18. CEO total compensation as printed in Verona Pharma plc's own proxy. As printed: 19,456,473. View filing ↗
- SpringWorks Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. View filing ↗
- Ligand Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Ligand Pharmaceuticals Inc.'s own proxy. As printed: 11,472,095. View filing ↗
- Morphic Holding, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Morphic Holding, Inc.'s own proxy. As printed: 8,907,684. View filing ↗
- Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
- Catalyst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. View filing ↗
- Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
- Xencor, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. View filing ↗
- Innoviva, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-03-24. CEO total compensation as printed in Innoviva, Inc.'s own proxy. As printed: 5,400,197. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Xeris Biopharma Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Xeris Biopharma Holdings, Inc.'s own proxy. As printed: 5,042,584. View filing ↗
- Savara Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Savara Inc.'s own proxy. As printed: 4,845,000. View filing ↗
- Amarin Corporation plc, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Amarin Corporation plc's own proxy. As printed: 3,540,366. View filing ↗
- Coherus BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences, Inc.'s own proxy. As printed: 2,736,874. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Theravance Biopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Theravance Biopharma, Inc.'s own proxy. As printed: 1,472,019. View filing ↗
- Section 10a, Amarin Corporation plc reciprocity. DEF 14A. Amarin Corporation plc names Innoviva, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ligand Pharmaceuticals Inc. reciprocity. DEF 14A. Ligand Pharmaceuticals Inc. names Innoviva, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗